Acute Intermittent Porphyria Clinical Trial
Official title:
Observational Study of Acute Intermittent Porphyria Patients
This is an observational prospective study that will allow evaluating the clinical and
laboratory parameters evolution of at least eight patients with AIP.
This study will allow establishing a baseline for the evaluation of the eight patients that
are planned to be included in a gene therapy clinical trial (AAVPBGD-AIP-001) for the AIP
treatment using a rAAV5-AAT-cohPBGD expression.
Patients fulfilling the study inclusion criteria will undergo a clinical and laboratory
evaluation for a minimum of 6 months (with one inclusion visit, one final visit and at least
two visits of follow up) up to a maximum of 24 months until their inclusion in the
subsequent clinical trial.
A complete evaluation of the clinical (symptoms and quality of life assessment) and
laboratory (blood and urine) data will be collected.
Acute Intermittent Porphyria (AIP) is inherited as an autosomal dominant disorder of the
heme biosynthesis pathway. AIP is caused by a genetic defect in porphobilinogen deaminase
(PBGD) a key enzyme for heme synthesis.
AIP is characterized by acute episodes and asymptomatic periods. Neuropathic symptoms are
predominantly in these attacks, which may be related to the toxic effect produced by the
precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), accumulated because
the enzyme deficiency. It occurs with very low prevalence (1 in 50,000), but figures for
prevalence based on clinical manifestations (i.e., acute attacks) greatly underestimate the
number of patients with latent AIP.
Abdominal pain is the most common symptom, sometimes with constipation. Paraesthesias and
paralysis also occur, and death may result from respiratory paralysis. Many other phenomena,
including seizures, psychotic episodes, and hypertension, develop during acute attacks
(Kadish 1999, Anderson 2007). Acute attacks rarely occur before puberty. They may be
precipitated by porphyrogenic drugs such as barbiturates, progestogens and sulfonamides,
some of which are known to induce the first rate-controlling step in heme synthesis, ALA
synthesis. Other known precipitants are alcohol, infection, starvation, and hormonal
changes; attacks are more common in women.
This is a pre-treatment observational study designed to collect clinical and laboratory data
to later compare baseline and post-treatment variables in a future clinical trial
(AAVPBGD-AIP-001) for the AIP treatment using a recombinant adeno-associated virus vector
with a liver-specific promoter for the PBGD expression (rAAV5-AAT-cohPBGD).
The PRIMARY OBJECTIVE is to observe the changes of PBG and ALA urinary levels in AIP
patients.
The SECONDARY OBJECTIVES are:
- To observe and document the frequency of acute attacks, the nature and frequency of
symptoms, medication and hospitalization requirements, neurological involvement,
psychological involvement and health-related quality of life of AIP patients.
- To record the use of concomitant medication in AIP patients.
At least eight patients fulfilling the inclusion/exclusion criteria will be included. No
sample size assessments have been taken into account due to the study nature, so this number
of patients is considered sufficient to meet the study objectives.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02922413 -
Panhematin for Prevention of Acute Attacks of Porphyria
|
Phase 2 | |
Completed |
NCT02949830 -
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
|
Phase 1/Phase 2 | |
Completed |
NCT02943213 -
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
|
Phase 1 | |
Completed |
NCT02082860 -
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
|
Phase 1 | |
Completed |
NCT03338816 -
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
|
Phase 3 | |
Completed |
NCT02452372 -
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
|
Phase 1 | |
Completed |
NCT00418795 -
Porphozym in the Treatment of Acute Attacks in AIP
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01617642 -
Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
|
||
Active, not recruiting |
NCT02935400 -
Acute Porphyria Biomarkers for Disease Activity
|